The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer (RAPTOR)
Patients with rheumatoid arthritis (RA) have an increased risk of lung cancer, potentially influenced by targeted therapies such as JAK inhibitors and biologics. Extracellular vesicles (EVs) are key mediators of intercellular communication and may carry biomarkers involved in oncogenesis. This study aims to compare EV concentration and molecular content in RA patients treated with different targeted therapies. The objective is to identify treatment-related differences in EV profiles that may contribute to lung cancer development and improve risk stratification.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
RA is associated with an increased incidence of lung cancer, with recent evidence suggesting a differential risk according to targeted therapies. The biological mechanisms underlying this association remain unclear. EVs are circulating nanovesicles involved in immune regulation and tumor progression, carrying proteins and nucleic acids that may reflect disease and treatment effects. This prospective monocentric observational study will include RA patients treated with JAK inhibitors, abatacept, anti-TNF, or anti-IL-6 therapies. A single additional blood sample will be collected during routine care. EV concentration will be measured, and their protein and miRNA content analyzed using omics approaches. Functional assays will assess the impact of EVs on bronchial epithelial and lung cancer cell lines.The study aims to identify EV-based biomarkers associated with specific treatments and potentially linked to lung cancer risk.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Pascale Vergne-Salle, Professor
- Telefonnummer: 05 55 05 55 55
- E-mail: pascale.vergne-salle@chu-limoges.fr
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients receiving rheumatology care at Limoges University Hospital with diagnosis of RA established
Beskrivelse
Inclusion Criteria:
- Patients receiving rheumatology care at Limoges University Hospital
- Aged 18 years or over
- Diagnosis of RA established in accordance with the 2010 ACR (American College of Rheumatology) / EULAR (European League Against Rheumatism) classification criteria
- Patients who have been treated with a JAK inhibitor, anti-TNF agent, abatacept or anti-IL-6 for at least 1 month
- Patients capable of expressing their refusal
- Patients with up-to-date health insurance cover
Exclusion Criteria:
- Pregnant or breastfeeding women
- Patients under a protective regime (guardianship, curatorship)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Patients being treated in the rheumatology department at Limoges University Hospital who have been d
Collection of additional blood tubes during a routine blood test |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma extracellular vesicle (EV) concentration at inclusion
Tidsramme: 6 months
|
Extracellular vesicle concentration will be measured, and their protein and miRNA content analyzed using omics approaches. Functional assays will assess the impact of EVs on bronchial epithelial and lung cancer cell lines.The study aims to identify EV-based biomarkers associated with specific treatments and potentially linked to lung cancer risk. |
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 87RI26_0028 (RAPTOR)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .